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Formulation and Evaluation of Bilayer tablets of Metformin hydrochloride SR and Vildagliptin IR
1. INTRODUCTION
1.1 DIABETES1
              Diabetes is  a chronic disease in which body does not make or properly use insulin, a
hormone  that  is  needed  to  convert  glucose  and  other  food  in  to  energy.  Diabetes  mellitus,
describes  a  group of  metabolic  diseases  in which the person has  high blood glucose (blood
sugar),  either  because  insulin  production  is  inadequate,  or  because  the  body's  cells  do  not
respond properly to insulin, or both. Patients with high blood sugar will typically experience
polyuria  (frequent  urination),  they  will  become increasingly thirsty  (polydipsia)  and  hungry
(polyphagia).
There are three types of diabetes: 
1). Type 1 Diabetes2, 3
The body does not produce insulin. Some people may refer to this type as  insulin-dependent
diabetes, juvenile diabetes, or early-onset diabetes. People usually develop type 1 diabetes before
their 40th year, often in early adulthood or teenage years. Type 1 diabetes is nowhere near as
common as type 2 diabetes. Approximately 10% of all diabetes cases are type 1.
2) Type 2 Diabetes
The body does not produce enough insulin for proper function, or the cells in the body do not
react to insulin (insulin resistance).Approximately 90% of all cases of diabetes worldwide are of
this type. Some people may be able to control their type 2 diabetes symptoms by losing weight,
following a healthy diet, doing plenty of exercise, and monitoring their blood glucose levels.
However, type 2 diabetes is typically a progressive disease - it gradually gets worse - and the
patient will probably end up have to take insulin, usually in tablet form. Overweight and obese
people have a much higher risk of developing type 2 diabetes compared to those with a healthy
body weight.  People  with  a  lot  of  visceral  fat,  also  known as  central  obesity,  belly  fat,  or
abdominal obesity,  are especially at  risk.  Being overweight/obese causes the body to release
chemicals  that  can  destabilize  the  body's  cardiovascular  and  metabolic  systems.  Being
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overweight,  physically  inactive  and  eating  the  wrong  foods  all  contribute  to  our  risk  of
developing type 2 diabetes.
3) Gestational Diabetes
This type affects females during pregnancy. Some women have very high levels of glucose in
their blood, and their bodies are unable to produce enough insulin to transport all of the glucose
into  their  cells,  resulting  in  progressively  rising  levels  of  glucose.  Diagnosis  of  gestational
diabetes is made during pregnancy. The majority of gestational diabetes patients can control their
diabetes with exercise and diet. Between 10% to 20% of them will need to take some kind of
blood-glucose-controlling  medications.  Undiagnosed  or  uncontrolled  gestational  diabetes  can
raise the risk of complications during childbirth. 
MECHANISM OF ACTION OF INSULIN4- 6     
                 Insulin initiates the action by binding to a glycol protein receptor on the surface of the
cells. Insulin released in to the blood by blood by B cells in the pancreas response to rising levels
of  glucose.  Insulin  absorbs  glucose  from  blood  for  use  as  fuel,  conversion  other  needed
molecule, or for storage. Insulin converts glucose to glycogen for internal storage of liver and
muscle cells. Reduced the glucose levels result in both in reduced the level of insulin from B
cells and reverse conversion of glycogen to glucose, when glucose level falls. These mechanism
of action of insulin regulating the carbohydrate and lipid metabolism are illustrated in Fig 1.
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Categories and effects:
Five kinds of oral anti-diabetic drug7, 8are used to treat diabetes.
1. Sulfonyl urea’s: stimulate the pancreas to release insulin. 
2. Meglitinides : Stimulate the pancreas to release insulin. 
3. Biguanides : such as Glucophage reduce gluconeogenesis in the liver.
4. Thiazolidinediones: such as Actos improve insulin resistance.
5. Alpha-glycosidase inhibitors: such as Glucobay decrease glucose absorption from 
                       Small intestine.
Oral Anti-diabetic medicines are not recommended for:
1. People with Type 1 Diabetes.
2. Women who have had diabetes during pregnancy and breast feeding.
3. Patients who underwent major surgery.
4. People who are in massive pressure such as severe injury or infection.
5. People who have allergy history of oral anti-diabetic drugs.
6. People who have obvious heart failure or liver/renal function impairment
SIDE EFFECTS:
1. Sulfonylureas: The primary side effect is hypoglycemia and usually minor skin allergy.
2.   Meglitinides     : The primary side effect is hypoglycemia and minor symptoms are skin
                                   rash or itching; gastro-intestinal upset.
3.  Thiazolidinediones: The medication may cause fluid retention, edema or weight gain.
4.   Biguanides: The vexing side effect is lactic acidosis, especially using for those who were   
      comorbid with obvious heart failure or liver/renal function impairment. The minor side
effects are nausea, diarrhea and gastro-intestinal upset.
5.   Alpha-glycosidase inhibitors: The main serious side effect is liver function impairment and
     the less annoying side effects are flatulence or diarrhea.
Cautions:
1. Do not change your dosage or stop using your medicine without discussion with your doctor. 
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    Otherwise, the change of dosage may lead to high blood glucose level.
 2. If certain kinds of Sulfonylurea’s such as Gliben, Glidiab are taken, the patient should have  
    some food within 30 minutes.
 3. Do not titrate dosage of Sulfonylurea’s and Meglitinides by yourself, for these two types of  
    the medicines may cause hypoglycemia. The hypoglycemia is more likely to occur if you   
    have your meal irregularly.
 4. You might have symptoms, such as weakness, fatigue, dizziness, cold sweating, irritation,  
    palpitation, or hunger when facing hypoglycemia..
1.2 BILAYER TABLETS9 ,10
INTRODUCTION
      In  the  last  decade,  interest  in  developing  a  combination  of  two  or  more  Active
pharmaceutical ingredients (API) in a single dosage form (bi-layer tablet) has increased in the
pharmaceutical industry, promoting patient convenience and compliance. Bi-layer tablets can be
a primary option to avoid chemical incompatibilities between API by physical separation, and to
enable  the  development  of  different  drug  release  profiles  (immediate  release  with  extended
release).
NEED OF BILAYER TABLETS9 
1. For the administration of fixed dose combinations of different APIs, prolong the drug
    Product life cycle, buccal / mucoadhesive delivery systems; fabricate novel drug delivery   
    systems such as chewing device and floating tablets for gastro-retentive drug delivery.
2. Controlling the delivery rate of either single or two different active pharmaceutical    
    ingredient(s)
3. To modify the total surface area available for API layer either by sandwiching with one or    
    two inactive layers in order to achieve swellable/erodible barriers for modified release.
4. To separate incompatible Active pharmaceutical ingredient (APIs) from each other, to control  
    the release of API from one layer by utilizing the functional property of the other layer (such  
    as, osmotic property).
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ADVANTAGES OF THE BILAYER TABLET DOSAGE FORM9
1. Bi-layer execution with optional single-layer conversion kit.
2. Cost is lower compared to all other oral dosage form. Article
3. Greatest chemical and microbial stability over all oral dosage form.
4. Objectionable odour and bitter taste can be masked by coating technique.
5. Flexible Concept.
6. They are unit dosage form and offer the greatest capabilities of all oral dosage form for the
    greatest dose precision and the least content variability.
7. Easy to swallowing with least tendency for hang-up.
8. Suitable for large scale production.
DISADVANTAGES OF BILAYER TABLET DOSAGE FORM9
1. Some drugs resist compression into dense compacts, owing to amorphous nature, low
   density character.
2. Bitter tasting drugs, drugs with an objectionable odour or drugs that are sensitive to oxygen
    may require encapsulation or coating.
3. Difficult to swallow in case of children and unconscious patients.
4. Drugs with poor wetting, slow dissolution properties, optimum absorption high in GIT may
    be difficult to formulate or manufacture as a tablet that will still provide adequate or full drug
   bioavailability.
IDEAL CHARACTERSTICS OF BILAYER TABLETS9
1. A bi-layer tablet should have elegant product identity while free of defects like chips, cracks,
     discoloration and contamination.
2. It should have sufficient strength to with stand mechanical shock during its production
    packaging, shipping and dispensing.
3. It should have the chemical and physical stability to maintain its physical attributes over time.
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    The bi-layer tablet must be able to release the medicinal agents in a predictable and  
    reproducible manner.
4. It must have a chemical stability shelf-life, so as not to follow alteration of the medicinal    
   agents.
CHALLENGES IN BILAYER TABLETS MANUFACTURIE10 
Conceptually, bi-layer tablets can be seen as two single-layer tablets compressed into one. In
Practice, there are some manufacturing challenges.
Delamination: Tablet falls apart when the two halves of the tablet do not bond completely. The
two granulations should adhere when compressed.
Cross-contamination: When the granulation of the first layer intermingles with the granulation
of the second layer or vice versa, cross-contamination occurs. It may conquer the very purpose of
the  bi  layer  tablet.  Proper  dust  collection  goes  a  long  way  toward  preventing  cross
contamination.
Production yields:  To prevent cross contamination, dust collection is required which leads to
losses. Thus, bi layer tablets have lower yields than single-layer tablets.
Cost:  Bilayer  tableting is more expensive than single layer tableting for several reasons. First,
the tablet press costs more. Second, the press generally runs more slowly in blazer mode. Third,
development  of  two  compatible  granulations  is  must,  which  means  more  time  spent  on
formulation  development,  analysis  and  validation.  These  factors,  if  not  well
controlled/optimized, in one way or another will impact the bi-layer compression per se and the
quality attributes of the bi-layer tablets (sufficient mechanical strength to maintain its integrity
and individual layer weight control). Therefore, it is critical to obtain an insight into the root
causes to enable design of a robust product and process.
Types of bi-layer tablet press:
1. Single sided tablet press.
2. Double sided tablet press.
3. Bi-layer tablet press with displacement monitoring.
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1. Single sided press:
        The simplest design is a single sided press with both chambers of the doublet feeder
separated from each other. Each chamber is gravity or forced fed with different power, producing
the two individual layers of tablets. When die passes under the feeder, it is first loaded with the
first layer powder followed by the second layer powder. Then the entire tablet is compressed in
one or two steps.
Limitations of the single sided press:
1. No weight monitoring / control of the individual layers.
2. No distinct visual separation between the two layers.
3. Very short first layer dwell time due to the small compression roller, possibly resulting in poor
.   deaeration, capping and hardness problems.
4. This may be corrected by reducing the turret rotation speed (to extend the dwell time) but
    with the consequence of lower tablet output.
2. Double sided tablet press: 
In most double sided tablet presses with automated production control use compression force to
monitor  and  control  tablet  weight.  The  effective  peak  compression  force  exerted  on  each
individual tablet or layer is measured by the control system at main compression of the layer.
This measured peak compression force is the signal used by the control system to reject out of
tolerance and correct the die fill depth when required.
3. Bi layer tablet press with displacement monitoring:
The displacement tablet weight control principle is fundamentally different from the principle
based upon compression force.  When measuring displacement,  the control  system sensitivity
does not depend on the tablet weight but depends on the applied pre compression force.
Advantages:
1. Weight monitoring / control for accurate and independent weight control of the individual
     layers.
2. Low compression force exerted on the first layer to avoid capping and separation of the two
    Individual layers.
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3. Independence from the machine stiffness.
4. Increased dwell time at pre compression of both first and second layer to provide sufficient
    hardness at maximum turret speed.
5. Maximum prevention of cross-contamination between the two layers.
6. Clear visual separation between the two layers and maximized yield.
PREPARATION OF BILAYER TABLETS
Bi-layer tablets are prepared with one layer of drug for immediate release with the second layer
designed to release drug later, either as a second dose or in an extended release form8. The bi-
layer tablets with two incompatible drugs can also be prepared by compressing separate layers of
each drug so as to minimize area of contact between two layers. An additional intermediate layer
of  inert  material  may  also  be  included.  To  produce  adequate  tablet  formulation,  certain
requirements such as sufficient mechanical strength and desired drug release profile must be met.
At  times,  this  may be difficult  task for  formulator  to  achieve these conditions  especially in
bilayer tablet formulation where double compression technique is involved, because of poor flow
and compatibility characteristic of the drug which will result in capping and/or lamination. The
compaction of a material involves both the compressibility and consolidation.
Compression: it  is  defined  as  reduction  in  bulk  volume by eliminating voids  and  bringing
particles into closer contacts.
Consolidation: it is the property of the material in which there is increased mechanical strength
due to inter particulate interaction (bonding). The compression force on layer 1 was found to be
major factor influencing tablet delamination. The scheme of preparation of bilayered tablets is given
in Fig no.2.
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Fig No: 2 Compression Process of bilayered tablets
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QUALITY AND GMP-REQUIREMENTS
To produce a quality bi-layer tablet, in a validated and GMP-way, it is important that the Selected
press is capable of :
1. Preventing capping and separation of the two individual layers that constitute the bi-layer
     Tablet.
2. Providing sufficient tablet hardness
3. Preventing cross-contamination between the two layers
4. Producing a clear visual separation between the two layers
5. Obtaining yield Accurate and individual weight control of the two layers.
These requirements seem to be obvious but are not so easily accomplished.
RECENT DEVELOPMENTS IN THE FIELD OF BILAYER TABLETS
The introduction of bi-layer tablets into the pharmaceutical industry has enabled the development
of pre-determined release profiles of active ingredients and incorporation of incompatible active
ingredients into the single unit dosage form. Large number of work has been done in this field.
Some of the recently developed bilayered tablets presented table-1.
Table No 1: Various Advancements in the Field of Bilayer Tablets9
DRUG(S)  DOSAGE FORM  RATIONALE
Diclofenac, Cyclobenza-prine Bilayer tablets Synergistic effect in pain
Granisetron HC1 Bi-layer tablets To overcome bioavailability 
problem, reducing side effects
Metformin HC1, Glimipiride Bilayer tablets   Synergistic effect in diabetes
Indomethacin  Bi-layer floating tablets  floating tablets Biphasic drug 
release
Metformin HC1, Atorvastatin
Calcium
Bi-layer tablets To develop polytherapy for the 
treatment of
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NIDDS & hyperlipidemia
Cefixime Trihydrate, 
Dicloxacilline
Sodium
Bilayer tablets  Synergistic effect in bacterial 
infections
Piracetam, Vinpocetin Bilayer tablets  Synergistic effect in 
Alzheimer disease
Metformin HCl, Pioglitazone bilayer tablets Synergistic effect in diabetes 
mellitus
Atenolol Bilayer buccal tablets
To overcome bioavailability 
problem, reducing
side effects and frequency of 
administration
Cefuroxime Axetil ,Potassium
Clavulanate
Bilayer tablets Synergistic effect against 
microbial infections  and to 
minimize dose dependent side 
effects
Amlodipine  Besilate 
,Metoprolol
Succinate
Bilayer tablets Synergistic effect in 
hypertension
Diclofenac Sodium, 
Paracetamol 
Bilayer tablets Synergistic effect in pain
Ibuprofen, Methocarba-mol Bilayer tablets
  Synergistic effect of drugs in 
back pain
Atorvastatin Bilayer buccal tablets To overcome bioavailability 
problem, reducing
side effects and frequency of 
administration
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Atorvastatin, Calcium  Bilayer buccal tablets To overcome bioavailability 
problem, reducing
side effects and frequency of 
administration
Paracetamol, diclofenac Bilayer tablets Synergistic effect of drugs in 
pain
Losartan  Bilayer tablets  Biphasic release profile
Metformin HCl, Pioglitazone  Bilayer tablets  Synergistic effect in diabetes 
mellitus
Guaifenesin  Bilayer tablets  Biphasic release profile
Tramadol, Acetaminophen  Bilayer tablets  Synergistic effect of drugs in 
pain
Atenolol, Lovastatin  Bilayer floating tablets
Synergistic effect in 
hypertension and biphasic
release profile
Montelukast, Levocetrizine Bilayer tablets  To improve the stability of 
drugs in combination
Salbutamol, Theophylline  Bilayer tablets  Synergistic effect of drugs in 
asthma
Glipizide, Metformin HCL  Bilayer tablets  To avoid interaction b/w 
incompatible drugs
Telmisartan Hydrochlor- 
thiazide 
Bilayer tablets 
To minimize contact b/w 
hydrochlorothiazide &
basic component of telmisartan
Amlodipine, Atenolol Bilayer tablets To improve the stability of 
drugs in combination
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Ascorbic acid, Cyano-
cobalamin Double layer suppositories To avoid interaction b/w 
incompatible vitamins
Rifampicin, Isoniazid
Capsule & tablet in
Capsule
To avoid interaction b/w 
incompatible drugs
Misorostol, Diclofenac  Bilayer tablets  To minimize contact b/w 
drugs
1.3 CONTROLLED RELEASE DRUG DELIVERY SYSTEM12- 15
              Oral drug delivery is the most preferred and convenient option as the oral route provides
maximum active  surface  area  among all  drug delivery system for  administration  of  various
drugs.  The  attractiveness  of  these  dosage  forms  is  due  to  awareness  to  toxicity  and
ineffectiveness of drugs when administered by oral conventional method in the form of tablets &
capsules.  Usually  conventional  dosage  form  produces  wide  range  of  fluctuation  in  drug
concentration  in  the  bloodstream and  tissues  with  consequent  undesirable  toxicity  and  poor
efficiency. The maintenance of concentration of drug in plasma within therapeutic index is very
critical for effective treatment. These factors as well as factors such as repetitive dosing and
unpredictable absorption lead to the concept of oral  Sustained release drug delivery systems.
Sustained release12 - 16 drug delivery system works on many different mechanisms to control the
release rate of drugs. Developing oral  sustained release matrix tablets for drug with constant
release rate has always been a challenge to the pharmaceutical technologist. Drug release through
matrix system is determined by Water penetration, Polymer swelling, Drug dissolution, Drug
diffusion, Matrix erosion have been utilized as formulation approaches. 
             Over the Past 30 years, as the expense and complications involved in marketing new
drug  entities  have  increased,  with  concomitant  recognition  of  the  therapeutic  advantages  of
Sustained drug delivery, greater attention is being paid on development of oral sustained release
drug delivery systems. The goal in designing sustained release drug delivery system is to reduce
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the frequency of the dosing, reducing the dose & providing uniform drug delivery. So, Sustained
release  dosage  form  is  a  dosage  form  that  releases  one  or  more  drugs  continuously  in
predetermined pattern for a fixed period of time, either systemically or locally to specified target
organ 1-3. Sustained release dosage forms provide better control of plasma drug levels, less 
 
.              Hydrophilic polymer matrix  is widely used for formulating an Sustained dosage form.
The role of  ideal  drug delivery system is to provide proper  amount of  drug at  regular  time
interval & at right site of action to maintain therapeutic range of drug in blood plasma. The
primary rate limiting ingredients of hydrophilic matrix are polymers that would swell when in
contact  with aqueous solution and form a gel  layer  on the surface of  the system.  When the
release medium is thermodynamically compatible with a polymer, the solvent penetrates into the
free spaces between macromolecular chains. The polymer may undergo a relaxation process due
to the stress of the penetrated solvent, so that the polymer chains become more flexible and the
matrix swells. This allows the encapsulated drug to diffuse more rapidly out of the matrix. On
the  other  hand,  it  would  take more  time for  drug to  diffuse  out  of  the  matrix  since  matrix
swelling lengthens the diffusion path. It has been widely known that swelling and diffusion are
not the only factors that  determine the rate of drug release.  For dissolvable polymer matrix,
polymer dissolution is another important mechanism that can modulate the drug delivery rate.
While  either  swelling  or  dissolution  can  be  the  predominant  factor  for  a  specific  type  of
polymers,  in  most  cases  drug  release  kinetics  is  a  result  of  a  combination  of  these  two
mechanisms. The presence of water decreases the glass transition temperature (Tg) (for HPMC
from 184°C to below 37°C), giving rise to transformation of glassy polymer to rubbery phase
(gel layer). The enhanced motility of the polymeric chain favors the transport of dissolved drug.
Polymer relaxation phenomena determine the swelling or volume increase of the matrix. The
main polymers used in hydrophilic matrices are hydroxyl propyl methyl cellulose (HPMC) and
Hydroxyl propyl cellulose (HPC), Xanthan gum, Carbopol and Alginates. The Sustained release
drug delivery system is very helpful in increasing the efficiency of the dose, safety of dose as
well as the patient compliance. Nowadays, the oral route of administration for Sustained release
drug delivery system has  received more attention due to its  more flexibility,  reduced dosing
frequency and better  patient  compliance.  The design of  oral  Sustained  release drug delivery
system depends on various factors  like,  physic-chemical  properties  of drug,  type of  delivery
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system,  disease  being  treated,  patient  condition,  treatment  duration,  presence  of  food,
gastrointestinal motility and co-administration of other drugs. From the above discussion, we can
concluded that Moreover; the reasonable cost of oral Sustained release drug delivery system has
lead ease of market penetration as replacement of oral conventional drug   release rate and the
proportion of total drug that can be incorporated into a matrix.
  
Fig No: 3 Sustained Release Of Drugs Through Matrix Diffusion.
Controlled release VS. Sustain release;17
   Difference between controlled and sustained release is that controlled is perfectly zero order
release that is, the drug is irrespective of concentration. on other hand, sustain release implies
slow release of drug over the time period. It may or may not be controlled release.
Limitations of oral conventional dosage form
  
1. Poor patient compliance, increased chances of missing the dose of a drug with short half life
for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to under medication or over
medication in narrow therapeutic index drug. 
3. A typical peak-valley plasma concentration time profile is obtained which makes attainment of
steady-state condition impossible
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Advantages of Sustained/Controlled release drug delivery18,19  system over the conventional
dosage form; 
1. Reduced dosing frequency. 
2. Dose reduction. 
3. Improved patient compliance. 
4. Constant level of drug concentration in blood plasma. 
5. Reduced toxicity due to overdose. 
6. Reduces the fluctuation of peak valley concentration. 
7. Night time dosing can be avoided. 
. 
2. LITERATURE REVIEW
 
 Durga Prasad Pattanayak  et al(2011) Attempted to design a formulation to improve
the oral therapeutic efficacy with optimal control of plasma drug level which contains two ant
diabetic  drugs  i.e.  Metformin  HCl  and  Glimepiride20.  Bilayer  tablet  formulation  has  been
developed  consisting  of  two  drug  containing  layers  which  comprises  Metformin  sustained
release  layer  and  an  immediate  release  layer  of  Glimepiride  was  optimized  separately  and
constituted  in  bilayer  tablet,  a  common  analytical  method  for  quantitative  combined  drug
Ultra College of Pharmacy, Madurai. Page 17
Formulation and Evaluation of Bilayer tablets of Metformin hydrochloride SR and Vildagliptin IR
estimation was employed and evaluated. Two different matrix formulations were developed, one
matrix  layer  with  hydrophilic  swellable  polymer  and  another  with  hydrophobic  polymer  as
carriers  for  sustained  drug  delivery  from  matrices  and  were  evaluated.  Hydroxyl  propyl
methylcellulose  and  Polyethylene  oxide was  used  as  polymers  in  order  to  get  the  sustained
release profile over a period of 24 h. Tablets were evaluated for physical properties; drug content
and  in  vitro  drug release  were  compared  with  standard  commercial  tablets  (Glimy-M).  The
excipients used in this formulation did not alter physicochemical properties of drug, as tested by
HPLC, DSC, and FTIR. Stability of the drug release profiles at 6 months in 40◦C and 75%RH
suggesting that  HPMC based sustained release formulation was stable than the Polyethylene
oxide sustained release formulation due to its stable and better targeting profile in terms of drug
release. This formulation also exhibited the best fitted formulation into zero order kinetics and
non-Fickian transport of the drug from the tablets was confirmed. Bilayer tablet prepared from
optimized formula was found to be best suited method for fixed dose combination of sustained
release Metformin HCl and immediate release Glimepiride. 
S.Brito  Rajet  al  (2011),  Bilayered  tablet  of  Metformin  hydrochloride  (SR)  with
Metoprolol tartarate21  (IR) as a once daily formulation. The formulations of tablets (B1- B10)
were prepared by using release retarding agents like HPMC K100, Eudragit S 100 for sustained
release (SR) layer and super disintegrants like Crosspovidone  Sodium starch glycolate (SSG) for
immediate release (IR) layer. Both sustained and immediate release granules were evaluated for
flow property. Bilayer tablets were evaluated for weight variation, hardness, thickness, swelling
index  and  in-vitro  drug  release  for  12  hours.  All  the  formulations  obey Zero  order  release
kinetics and the mechanism of drug release was found to be non fickian diffusion by fitting the
data  to  peppas  equation.  The  result  suggest  that  the  developed  Bilayer  tablet  of  Metformin
hydrochloride  (SR)  with  Metoprolol  tartarate  (IR)  could  perform  therapeutically  better  and
improve  efficacy  than  conventional  dosage  forms,  and  also  it  trounce  the  severe  diabetic
complication especially hypertension.
 Rikin  Patel  et  al  (2013).  Validated  process  of  preparation  of  bilayered  tablets  of
Metformin  hydrochloride  and  Glimipride22.Three  process  validation  batches  of  same  size,
method, equipment and validation criteria were taken. The critical parameters involved in sifting,
granulation  (dry  mixing,  wet  mixing,  drying,  milling,  lubrication),  pre  compression  and
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compression  were  identified  and  evaluated.  Different  stages  of  manufacturing  process  were
evaluated for acceptable granulation process and moisture content of granules after granulation;
acceptable moisture content after drying; acceptable particle size distribution, blend uniformity,
bulk  density  after  lubrication;  weight  variation,  thickness,  hardness,  %friability,  dissolution,
disintegration  after  compression.  The  outcome  indicated  that  this  process  validation  data
provides  high  degree  of  assurance  that  manufacturing  process  produces  product  meeting  its
predetermined  specifications  and  quality  attributes.  So,  manufacturing  process  of  Metformin
HCl30 and Glimepiride bi layer tablet was considered as validated.
          G. Hemanth Kumar et al (2012) Formulated and evaluate bilayer tablets of Metformin
Hydrochloride  and  Sitagliptin  Phosphate  as  fixed  dose  combination  tablets  for  effective
treatment  of  type  II  diabetes  mellitus23.  Preformulation  studies  including  drug  excipient
compatibility were conducted for both drugs. Different formulations of sustained release, floating
Metformin  Hcl  tablets  were  prepared  by using hydrophilic  polymers  like  HPMC K100  and
Sodium CMC and were evaluated.  Sitagliptin  immediate release formulations were prepared
using crosspovidone, croscarmellose sodium and sodium starch glycolate as superdisintegrants
and were evaluated. Based on the in vitro dissolution data F7 and S9 were selected as the best
formulations  from Metformin  and  Sitagliptin  formulations  respectively.  Bilayer  tablets  were
prepared by slightly compressing Metformin layer (F7) and then final compression was made by
placing Sitagliptin layer (S9) layer on it with final hardness 6.5 kg and they were evaluated.
From the bilayer tablet Sitagliptin layer disintegrated in 52 sec, Metformin layer started floating
after  5.2  min  and  gave  total  floating  time  18-24  hrs  with  good  swelling  index,  good  post
compression parameters. In  vitro dissolution study of bilayer tablet was done in USP type II
along with UV spectrophotometer gave cumulative % drug release of Sitagliptin as 99.15% at 30
min and 97.65 % of Metformin at  12 hrs. From the study it  was found that, combination of
HPMC  K100  and  Sodium  CMC  gave  good  sustained  release  for  12  hrs.  Among  the  3
superdisintegrants used sodium starch glycolate showed good disintegration of sitagliptin layer. 
        Vyas Jigar et al (2013) Bilayered gastro-retentive tablet containing MetforminHCl and
Pioglitazone  HCl  for  treatment  of  type-II  diabetes  mellitus  was  formulated24 .  To  make the
system more effective, combination of immediate layer, PioglitazoneHCl 15mg and sustained
release layer of Metformin HCl 500mg were prepared. The core tablet of MetforminHCl was
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prepared by using different swellable polymers like HPMC E15, HPMC K100 and carbopol by
wet granulation method and evaluated for swelling index, total floating time and floating lag
time. In vitro release studies were carried out with 0.1N HCl using USP dissolution apparatus 2
(paddle). Tablet thus formulated using HPMC K100M and E15 provided sustained release of
Metformin HCl over a period of 10 hours. The immediate release layer of PioglitazoneHCl was
prepared  by  using  crosspovidone,  a  super  disintegrant  by  direct  compression  method  and
evaluated for disintegration time and dissolution also. Then bilayered tablet was prepared with
the  selected  core  tablet  batch  of  MetforminHCl  followed  by  compression  coating  with  the
selected immediate release layer of PioglitazoneHCl. The present study concluded that bilayered
tablet can be a good way to treat diabetic patients with combination therapy. 
Gundaraniya PV et al  (2013) Developed bilayer tablets containing sustained release
microspheres as one layer and immediate release as another layer25. The proposed dosage form is
intended to decrease the dosing frequency and the combined administration of an anti-diabetic
agent. Several pharmaceutical companies are currently developing bi-layer tablets, for a variety
of reasons: patent extension, therapeutic, marketing to name a few. To reduce capital investment,
quite often existing but modified tablet presses are used to develop and produce such tablets. One
such approach is using microspheres as carriers for drugs also known as micro particles. It is the
reliable means to deliver the drug to the target site with specificity, if modified, and to maintain
the desired concentration at the site of interest. Microspheres received much attention not only
for prolonged release, but also for targeting of ant diabetic drugs. Bilayer tablet via microsphere
is new era for the successful development of controlled release formulation along with various
features to provide a way of successful drug delivery system. Especially when in addition high
production output is required. An attempt has been made in this review article to introduce the
society to the current technological developments in bilayer and floating drug delivery system.
 Ananda Kumar Chettupalli  et  al  (2013)  developed a  bi  layer  tablet  of  immediate
release Pioglitazone and controlled release Metformin Hydrochloride, which is used as an Anti-
hyperglycemic agent26. Metformin Hydrochloride has biological half-life nearly about 6 hours,
so, an attempt was made in the direction of preparation and optimization of a combination of
Sustained release and immediate release in a single tablet. In controlled release layer natural
gums like xanthum gum, gum trgacanth and guar gum were used as retarding materials and in
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immediate release layer  cros carmellose sodium was used as a super disintegrent to give the
faster release of pioglitazone. The tablets were prepared by wet granulation method and by direct
Compression.  Granules  were evaluated  for  pre compression parameters  and the tablets  were
evaluated for post compression parameters. 
 Pamu. Sandhya et al (2014) Prepared bilayer tablets of Glimepride and Metformin HCL
in combination27.  Metformin hydrochloride and Glimepiride are oral  hypoglycemic drug and
effectively used in treatment of diabetes mellitus (type-2 diabetes). The main aim of the present
study was to formulate Metformin hydrochloride37 sustained release and Glimepride immediate
release matrix tablets as a dosage form by different polymers such as HPMC, Povidone, Lactose
Monohydrate, Ethyl cellulose, Microcrystalline Cellulose and study the invitro release patterns of
the drug. In the present study bilayer tablets Glimepride prepared by direct compression method
and Metformin prepared by wet granulation technology. The prepared tablets were evaluated for
various physicochemical parameters such as drug-excipient interaction by FTIR, flow properties,
hardness, weight variation, friability, and in vitro dissolution studies optimized based on desired
sustained release time (16hrs) and acceptable floating properties The FTIR study revealed that
there is no drug-excipient interaction. During preformulation it has been observed that there is no
drug- drug and drug excipient interaction, so the excipients which have been selected for the
formulation are compatible with the drugs. This system provides zero order or near zero order
release for IR layer and SR layer provides Higuchi model.
 
 Goswami, Laxmi et al (2011) Dealt with the formulation and evaluation of combined
floating controlled drug delivery system using Metformin hydrochloride along with Pioglitazone
hydrochloride as a bilayer tablet formulation for prolonged gastric residence time28. Metformin
and  pioglitazone  hydrochloride  has  been  used  as  an  oral  hypoglycemic  agent  for  control  of
diabetes.  The fabrication of  bilayer  floating tablet  was done by modified direct  compression
using polymer like hydroxypropylmethyl cellulose (HPMC), carbopol, polyvinyl pyrrolidone to
facilitate immediate release of pioglitazone and sustained release of metformin. The formulated
tablets  were  subjected  to  various  evaluation  parameter  including  floating  lag  time,  floating
duration, drug content and spectrophotometric simultaneous estimation. The in-vitro dissolution
studies were performed by USP-II type dissolution apparatus in 900ml 0.1(N) HCl medium (pH-
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1.2) at 50 rpm and 37±0.5°C. Formulated tablets remain buoyant over a period of 12-20 hrs and
released more than 80% of drug in study period.
 
JYOTSNA GODBOLE et  al  (2012)  Designed  the  concept  of  bilayer  matrix  tablets
containing Acarbose as immediate release component using sodium starch glycolate and cross
carmillose  sodium  as  super  disintegrates  and  Metformin  hydrochloride  (HCl)  for  sustained
release by using hydroxyl propyl methyl cellulose (HPMC K 4M), (HPMC K 100) and sodium
carboxyl methyl cellulose (SCMC) as the matrix forming polymer and PVPK-30 as binder29.
Matrix  tablet  are  the  type  of  controlled  drug  delivery  systems,  which  release  the  drug  in
continuous manner. These release the drug by both as well as diffusion controlled mechanisms
metformin  HCl  is  6.2  hrs,  so  an  attempt  was  made  in  the  direction  of  preparation  and
optimization of a  combination of  sustained release and immediate release in a  single tablet.
Tablets were prepared by wet granulation and direct compression method. Tablets were evaluated
for post compression parameters. The tablets were evaluated for physico-chemical property. All
the values were found to be satisfactory. Invitro release studies were carried as per USP in water
and phosphate buffer of pH 6.8 using the apparatus I. The final preparation showed release of
drug up hours. FTIR studies revealed that there is no interaction between the drug and other
excipients used in the study.
              Chantal Mathieu and Evy Degrande  et al (2008).Carried out an extensive clinical
program  involving  approximately  22,000  patients  and  7000  patient-years  of  exposure  to
vildagliptin has shown that the agent is well tolerated and efficacious in improving glycemic
control in patients with type 2 diabetes mellitus (T2DM)30. Monotherapy trials have shown that
significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low
risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable
partner for combination therapy. Studies of vildagliptin as an add-on to metformin have shown
significant improvements in glycemic control (comparable to that of thiazolidinedione add-on),
with the combination being well tolerated and associated with low risks for hypoglycemia and
adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements
in  glycemic  control  have  also  been  observed  with  vildagliptin  as  an  add-on  treatment  to
sulfonylurea,  thiazolidinedione,  or  insulin  treatment  or  in  initial  combination  treatment  with
pioglitazone. Improved β-cell function and glycemic control have been shown with vildagliptin
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in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with
some evidence in the latter suggesting the potential for modifying disease course.
        James E. Signorovitch, et al (2011) Aimed at comparing 12-week glycaemic control with
vildagliptin 50 mg twice daily versus sitagliptin 50 or 100 mg once daily in Japanese patients
with type 2 diabetes31. Two trials of vildagliptin and three trials of sitagliptin were identified for
Japanese patients. Across all included trials, a total of 264 patients were treated with vildagliptin
50 mg twice daily, 235 were treated with sitagliptin 50 mg once daily and 145 were treated with
sitagliptin 100 mg once daily. Mean baseline HbA1c ranged from 7.4% to 7.8% per trial. Before
matching, significant (p<0.05) cross-trial differences included lower mean HbA1c (by 0.2–0.3%)
and higher FPG (by 5–13 mg/dl in vildagliptin trials. After matching, all baseline characteristics
were balanced between treatment groups. Combining matched trials, vildagliptin 50 mg twice
daily was associated with significantly greater absolute HbA1c reduction by 0.28% compared
with sitagliptin 50mg once daily (95% CI 0.15, 0.41; p<0.001) and by 0.35% compared with
sitagliptin  100mg once  daily  (95%  CI  0.07,  0.62;  p  =  0.013).  After  adjusting  for  baseline
differences among trials of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes,
vildagliptin 50 mg twice daily was associated with significantly greater HbA1c reduction than
sitagliptin 50 mg or 100 mg once daily.
               Ashutosh Kumar et al (2012) formulate and evaluate the bilayer tablet containing
Metoprolol succinate as sustained release and Ramipril as an immediate release layer32. The
sustained release32 part  was formulated by using hydrophilic  polymer HPMC K - 100 and
HPMC K4M. HPMC K4M was kept constant in a concentration of 10% for 5 formulations and
0.7% was increased in case of the 6th formulation. Metoprolol succinate is a beta 1-selective
(cardio selective) adrenoceptor blocking agent its chemical name is (I) - (isopropyl amino) -3-
(p-(2methoxy ethyl)  phenoxyl)-2-propanol  succinate  & Ramipril  is  a  2-aza-bicyclo  [3.3.01-
octanc-3-carboxylic acid derivative. It is a white, crystalline substance soluble in polar organic
solvents and buffered aqueous solutions. Ramipril melts between 105°C and 112°C.Ramipril
chemical  name  is  (2S,  3aS,  6aS)-l  [(S)-N-[(S)-l-Carboxy-3-phenylpropyl]  alanyl]
octahydrocyclopenta  [b]pyrrole-2-carboxylic  acid,  1-ethyl  ester.  In  the  Sustained  Release
formulation F6, using HPMC K100 56.7% and HPMC K4 M 10.7% gives the drug release of
15.6%, 34.9%, 54.19%, 80.25 %, 95.5% at IST, IVth, VIIIth and XXth hour respectively. As the
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polymer ratio increases the release rate of the drug decreases from the matrix tablet formulation
is  various  physiological  pH conditions.  All  the tablet  formulations  were  evaluated for  their
characteristics  such as  hardness,  thickness,  diameter,  friability,  weight  variation and content
uniformity (assay). From the investigation it was noted that the drug content were found to fall
within  the  limits.  From  this  study  it  can  concluded  that  Ramipril  and  Metoprolol  can  be
formulated with Metoprolol as sustained release layer by using HPMC K -100. The release can
be so well  controlled that it  almost coincides the theoretical release pattern for the drug by
proper adjustment of polymer ratio. Ramipril is formulated as one layer as immediate release.
Hence  this  dual  release  formulation  designed  was  found  to  be quite  useful  in  combination
therapy
3. SCOPE, OBJECTIVES AND PLAN OF WORK
Glucose lowering by anti diabetic drug in the diabetic management cannot be maintained over a
long period of time with the use of conventional dosage forms. Also probability of plasma level
fluctuation and missed dosages is higher.
    Two or more drugs from pharmacological action are needed to achieve adequate blood glucose
control.  single  dose  combination  anti  diabetic  therapy is  an  important  option  that  combines
efficacy of blood glucose reduction and low side effect profile with convenient once daily dosing
to enhance the compliance.  Because of  the lower  dose  of  anti  diabetic  drug,  metabolic  and
clinical events are decreased. The primary aim of treatment is to lower blood glucose to a normal
level using whatever combination of drug that achieves the goal.
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The rationale for using fixed dose combination therapy is to improved blood glucose control.
Employing two anti diabetic drug can also minimize the clinical and metabolic effects that occur
with  maximal  dosages  of  individual  components  of  the  combined  tablet.  This  has  potential
advantage as suggested some investigation have recommended using combination anti diabetes
therapy as initial therapy as initial treatment, particularly in patients with target organ damage or
more severe initial level of diabetes,
To reduce the frequency of  administration and improve the patient  compliance a  once daily
sustained release formulation is desirable. The most commonly used method of controlling the
drug  release  includes  the  drugs  in  a  matrix  system.  Because  of  their  flexibility  hydrophilic
polymer matrix system are widely used in oral controlled drug delivery to obtain desirable drug
release profile, cost effectiveness, and regulatory acceptance.
AIM OF WORK
      To develop once novel daily bilayer tablet of metformin hydrochloride as a sustained release,
vildagliptin as immediate release. 
The bilayer tablet containing sustains release part and immediate release part is administered, the
immediate release part is used to achieve therapeutic level immediately and it act as a loading
dose. The sustained part releases the drug for prolonged period and act as the maintenance dose.
             Metformin hydrochloride the hepatic glucose production,  decrease the intestinal
absorption of glucose and improve the insulin sensitivity by increasing the peripheral glucose
uptake  and  utilization.  the  maintenance  the  constant  plasma  level  of  anti  diabetic  drug  is
important in ensuring the desire therapeutic response. It reduces the blood glucose by reduction
of insulin level and maintains the blood glucose level.  Vildagliptin inhibits dipeptidyl peptidase-
4  (DPP-4).  This  in  turn  inhibits  the  inactivation  of  GLP-1  by  DPP-4,  allowing  GLP-1  to
potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose
regulation is thought to be through degradation of GIP and the degradation of GLP-1
OBJECTIVES
1, To develop the SR matrix tablet formulation of Metformin hydrochloride. 
2, To develop the IR tablet of vildagliptin.
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3, To access the release patterns of both the drugs from a bilayer tablet (super dosage form). 
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PLAN OF WORK
1,Preformulation studies on drugs .
2, Calibration of metformin and vildagliptin by HPLC
3. Formulation development of SR containing metformin hydrochloride of bi layer tablet, to
    achieve programme sustained release
4. Formulation development of IR part containing vildagliptin of   bi layer tablet.
5. Compression of bilayer tablet.
6. Evaluation of bilayer tablet for
     a. Weight variation
     b. Friability
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    c. Thickness
    d. Disintegration
    e. Drug release.
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4. MATERIALS AND METHODS
4.1,MATERIALS USED
The following materials obtained from commercial sources were  used  for the formulation of
bilayer tablets
Table No: 2
S.NO MATERIAL SOURCE
1 Metformin hydrochloride Chiplun fine chemicals. Mumbai
2 Vildagliptin Gift  samples  from  Novaties  pharma.
Mumbai
3 Hydroxyl  propyl  methyl  cellulose
(Methocel K-100 MCR)
S.D.fine chem...ltd. Mumbai
4 Cross Carmellose sodium Loba Chemical.pvt ltd .India
5 Micro crystalline cellulose PH 102 Samsung fine Chemicals. Mumbai
6 Lactose BP(supertab 30 GR) Fisher ltd. Chennai
7 Sodium Starch glycollate Gift  samples  from  FDC   pharma,
Maharashtra.
8 Magnesium stearate Jain enterprises. Chennai
9 Hypromellose (methocel E 15 cps) S.D. fine chemicals .Mumbai
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4.2 INSTRUMENTS USED
The following materials were obtained from commercial used for the formulation of bilayer 
tablets Table No: 3
S NO EQUIPMENTS SOURCES
1 28 station double hopper bilayer press Cadmach, Mumbai
2 Rapid mixture granulator Remi,Mumbai
3 Double cone blendor Cadmach.Mumbai
4 Hardness tester Monosanto
5 Friability tester Electro lab Chennai
6 Disintegration apparatus Electro lab . Chennai
7 Dissolution apparaus Electro lab .Chennai
8 Weighinig balance Precisa, Mumbai
9 HPLC/SPD 10 AVP Shimaldu. JapanI
10 Uv spectrophoto meter Shimaldu. japanI
11 pH meter STL ltd. Chennai
12 refrgerator Whirlpool india.ltd.chennai
13 Vernier caliper Mututoyo, Goa
14 Sonicator pk 106 Bandelin sonorex, Mumbai
15 Sieves 30#,20#,40# !Bio hem.. Pvt ltd.  Mumbai
16 Vibro sifter Janath pharmaceutical, 
Mumbai
17 Tab density tester Electro lab, Chennai
4.3. DRUG PROFILE
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4.3.1. METFORMIN HYDROCHLORIDE33,34
Functional category
               Metformin hydrochloride is an anti diabetic drug from the bigunaide class of oral anti
hyperglycemic agents
Structure
Class                 :Guanidines
Subclass                 :Biguanides
Chemical name     : -(diamino methylidine)-3,3-dimethyl-gunadine1
Molecular Formula: C4H12ClN5
Molecular weight    : 165.63gm/mol
Iupac name              : N-N-dimethylimidocarbonimidic diamide hydrochloride
Category                  : Anti diabetic agent
Description                 : white to off white crystalline powder, odourless 
PKa                             : in acid :12.4
Solubility                    : freely soluble in water, slightly soluble in alcohol,
                                       Practically insoluble in acetone and in methylene chloride
Half life                       : 6.2 hours. Duration of action is 8-12 hours.
Ultra College of Pharmacy, Madurai. Page 31
Formulation and Evaluation of Bilayer tablets of Metformin hydrochloride SR and Vildagliptin IR
Pharmacokinetics35, 36
Absorption and Bioavailability
• The absolute bioavailability of a metformin hydrochloride 500 mg tablet  given under
fasting conditions
•  approximately 50-60%. Studies using single oral doses of metformin tablets of 500 mg
and 1500 mg,
• 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing
doses,
• This is due to decreased absorption rather than an alteration in elimination.
.
Metabolism and Elimination
Intravenous  single-dose  studies  in  normal  subjects  demonstrate  that  metformin  is  excreted
unchanged
in the urine and does not undergo hepatic metabolism (no metabolites have been identified in
humans)
nor biliary excretion. Renal clearance (see Table 1) is approximately 3.5 times greater than cre
atinine
 Pharmacodynamics 
Metformin is an oral anti hyperglycemic agent that improves glucose tolerance in patients with
NIDDM, lowering both basal and postprandial plasma glucose. Metformin is not chemically or
pharmacologically related to any other class of oral anti hyperglycemic agents. Unlike sulfonyl
ureas,  metformin does not produce hypoglycemia in either patients with  NIDDM or healthy
subjects and does not cause hyper insulinemia. Metformin does not affect insulin secretion.
Pharmacology
Mechanism of action34
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                     Metformin's  mechanisms  of  action  differ  from other  classes  of  oral
antihyperglycemic  agents.  Metformin  decreases  blood  glucose  levels  by  decreasing  hepatic
glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity
by increasing peripheral glucose uptake and utilization. These effects are mediated by the initial
activation by metformin of AMP-activated protein kinase (AMPK), a liver enzyme that plays an
important role in insulin signaling, whole body energy balance, and the metabolism of glucose
and fats. Activation of AMPK is required for metformin's inhibitory effect on the production of
glucose by liver cells. Increased peripheral utilization of glucose may be due to improved insulin
binding to insulin receptors. Metformin administration also increases AMPK activity in skeletal
muscle. AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in
insulin-independent glucose uptake. The rare side effect, lactic acidosis, is thought to be caused
by decreased liver uptake of serum lactate, one of the substrates of gluconeogenesis. In those
with healthy renal function, the slight excess is simply cleared. However, those with severe renal
impairment may accumulate clinically significant serum lactic acid levels. Other conditions that
may precipitate  lactic  acidosis include severe hepatic  disease and acute/decompensated heart
failure.the mechanism of action of metformin presented in fig no:5
ADVERSE REACTION
                                       Adverse reactions of a more intense character including epigastric
discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise
and headache might be seen.
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                          Fig No:5 Mechanism of action of Metformin
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4.3.2 .VILDAGLIPTIN37
Chemical name:        1-[(3-Hydroxy-adamant-1-ylamino)acetyl]-pyrrolidine-2(S)-carbonitrile 
Chemical structure:
Molecular formula      ; C17H25N3O2
Molecular weight       : 303.40
DESCRIPTION 
                       Vildagliptin is a white to slightly yellowish or slightly greyish crystalline powder
with a melting point/range of approximately 150oC. It is freely soluble in water.
PHARMACOLOGY38
Pharmacodynamics
Vildagliptin belongs to a class of orally active antidiabetic drugs (DPP-IV inhibitors) that appear
to  have multiple  functional  benefits  beyond simple blood-glucose control.  One of  these is  a
potential protective effect  on pancreatic beta cells,  which deteriorate in diabetes.  Vildagliptin
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appears to be safe, very well tolerated, and efficacious. Following a meal, gut incretin hormones
are  released.  The  most  important  incretin  hormones  are  GLP-1  and  glucose-dependent
insulinotropic polypeptide (GIP).  These hormones, secreted in the human small intestine, are
responsible for insulin release due to increased glucose levels. In contrast to agents that promote
insulin  secretion  via  glucose-independent  mechanisms,  GLP-1's  dependence  on  glucose
concentration is considered beneficial due to a lower risk of hypoglycemia. GLP-1 also inhibits
glucagon secretion and increases  beta cell  mass  by stimulating proliferation and neogenesis.
However,  the clinical  utility of  GLP-1 is  limited by its  short  half-life (2 minutes).  GLP-1 is
rapidly degraded by the proteolytic enzyme DPP-IV. To enhance GLP-1 activity, inhibition of the
DPP-IV enzyme  is  emerging  as  a  novel  therapeutic  approach  in  the  treatment  of  diabetes.
Administration  of  vildagliptin  enhances  GLP-1's  ability  to  produce  insulin  in  response  to
elevated concentrations of blood glucose, inhibit the release of glucagon following meals, slow
the rate of nutrient absorption into the bloodstream, slow the rate of gastric emptying, and reduce
food intake
 
Absorption
                 Rapidly absorbed following oral administration with an oral bioavailability of greater
than 90%
Distribution
                The plasma protein binding of vildagliptin is low (9.3%), and vildagliptin distributes
equally between plasma and red blood cells
half life         : The elimination half-life is approximately 90 minutes
MECHANISM OF ACTION  
                              Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the
inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta
cells.  Dipeptidyl  peptidase-4's  role  in  blood  glucose  regulation  is  thought  to  be  through
degradation of GIP and the degradation of GLP-1(fig no:6)
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FIG NO: 6 MECHANISM OF ACTION OF VILDAGLIPTIN
       
       VILDAGLIPTIN
INHIBITION
DPP-4
DPP-4
INACTIVATION OF
GLP-1 BLOCKED
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4.3.3. EXCIPIENTS PROFILE
 Table No 4:  EXCIPIENTS PROFILE40, 39
S NO EXCIPIENTS PROPERTIES USES
1 MICRO CRYSTALLINE 
CELLULOSE BP(PH 102)
Fine or granular, white, 
odourless
In Soluble in water, slightly 
soluble in Noah, PH Between
5-7.5
Suspending 
agent,adjuvant
2 LACTOSE BP(SUPER TAB 30 GR) white, odourless, crystalline 
powder, freely but slowly 
soluble in water, practically 
insoluble in ethanol
Pharmaceutical aid
3 SODIUM STARCH GLYCOLLATE Very fine, white or off white, 
odourless, practically in 
soluble in water ,insoluble 
most organic solvents
Pharmaceutical 
aid(tablet 
disintegration)
4 MAGNESIUM STERATE Colourless crystals or white, 
odourless, very soluble in 
boiling water, practically 
insoluble in ethanol,
Pharmaceutical aid 
(lubrication)
5 HYPROMELLOSE(Methocel K-100 
MCR)
HYPROMELLOSE(Methocel  E 15 
CPS) (HYDROXY PROPYL METHYL
CELLULOSE)
White or yellowish white, 
fibrous or granular powder, 
odourless, practically 
insoluble in hot water, 
acetone, ether, toluene.
Pharmaceutical aid
(tablet excipients, 
suspending agent)
6 CROSS CARMELLOSE SODIUM White or almost white, Pharmaceutical 
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odourless , practically 
insoluble in acetone ,ethanol, 
toluene and ether, easily 
dispersed in water.
aid(Suspending agent,
viscosity increasing 
agent, excipients)
5 .METHODS (EXPERIMENTAL)
5.1  SIMULTANENEOUS  ESTIMATION  OF  VILDAGLIPTIN  AND  METFORMIN
HYDROCHLORIDE
The analytical method followed was HPLC which is  as follows.
ASSAY:
Equipment                 : HPLC  
Column                     : intertsil ODS-3VC18,150 mm X 4.6mm,5µm or equivalent
Wavelength               : 260 nm 
 Temperature             : ambient
Flow rate                   : 1.0ml/min
Injection volume       : 20µ/ml
Run time                   : about 10 min
Mobile phase             : filtered and degassed mixture buffer, acetonitrile; buffer (40;60v/v)..
Buffer: Dissolve 2.87gm of potassium di hydrogen phosphate in 300 ml water, dilute 1000 ml
with water and adjust to the pH to 7.0 with sodium hydroxide.
Diluents: pH 6.8 buffer
Standard preparation: 
1, Dissolve about 16 mgm of vildagliptin phosphate in 10 ml dissolution medium, dissolve and
dilute to 50 ml mobile phase.
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2, Dissolve about 125 mgm of metformin hydrochloride in 10 ml of mobile phase, and dilute 50
ml of mobile phase. Further take 5 ml solution (1) and (2) in50 ml volumetric flask, make up the
mobile phase to 50 ml. filter the solution through 0.45micron membrane filter.
Sample preparation:
                            Weigh and powder 20 tablets take 250 mg equivalent of metformin
hydrochloride in 10 ml of mobile phase, in 10 ml of mobile phase and dilute 100 ml with the
same solvent.  Further dilute five ml of  5ml with  mobile phase.  .  Filter  the solution through
0.45micron membrane filter
Procedure:
       Inject 20 µl volumes of blank, standard and sample preparation and record the peak response
for major peaks.
Chromatograph  the  standard  preparation,  sample  preparation  and  record  the  peak  responses
directed under the procedure. The test is not valid unless. 
a) The theoretical plates for of metformin hydrochloride peak in standard preparation are
not less than 2000.
b) The tailing factor of metformin hydrochloride peak in standard preparation is not more
than 2.0
    c)   The relative standard deviation for six replicate injection of standard preparation is not
       more than 2.0%    
   For vildagliptin
               calculate the mg vildagliptin from the declared content of vildagliptin phosphate
using  the following expression
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 Where, 
                             AT = Area of vildagliptin in sample preparation
                            AS = Area of vildagliptin in standard preparation
                           WS = weight of vildagliptin working standard in mg
                           WP = weight of vildagliptin working sample in mg
                              P =purity of vildagliptin phosphate on unhydrous basis
407.32 and 523.32 are the molecular weight of vildagliptin and vildagliptin phosphate.
                             
                             =              mg content of vildagliptin
                             =             mg/label claim x100
                             =             % content of vildagliptin
For metformin hydrochloride
Calculation; calculate the mg metformin hydrochloride and vildagiliptin in the tablet form the
 following expression =
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                             =                mg content of metformin hydrochloride
                             =                 mg/lable claim x100
                             =               % content of metformin hydrochloride
        Where,
                       AT = Area of metformin hydrochloride in sample preparation
                       AT = Area of metformin hydrochloride in standard preparation
                       WS = weight of metformin hydrochloride working standard in mg
                       WP = weight of metformin hydrochloride working standard in mg
                          P = purity of metformin hydrochloride working sample in mg
              
5.2 FORMULATION DEVELOPMENT 
PREPARATION OF BILAYER TABLETS
1, PREPARATION OF VILDAGLIPTIN IR GRANULES
The formula followed is given in table 5 
Table No: 5
S No Name of the ingredients Quantity
(mg)
Blendings: (for 1 tablet)
1 vildagliptin 50.0
2 Microcrystalline cellulose BP(PH 102) 84.2
3 Lactose BP (super tab GR) 47.8
4 Sodium starch glycolate BP 6.0
Lubrication:
5 Magnesium stearate 2.0
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STEP 1 SIFTING MATERIALS
All the ingredients were weighed  and metioned below according to the formula and pass 
through sieve no 40 #
S No Name of the ingredients Seiv
e no
1 vildagliptin 40#
2 Microcrystalline cellulose BP(PH 102) 40#
3 Lactose BP (super tab GR) 40#
4 Sodium starch glycolate BP 40#
5 Magnesium sterate 40#
STEP 2 MIXING AND GRANULATION
1.    Shifted material loaded from the step 9 was  loaded in to the rapid mixer granulator
1. The materials were mixed for 20 mints
2. The granulation was continued till coherent mass was obtained.
3. The granules was unloaded in to HDPE container line with double line poly ethylene bag 
the container  
 STEP 3 SHIFTING AND MILLING
• The dry granules were shifted through  sieve no 40# 
• The retains granules  through 0.5 mm screen   
STEP 4 FINAL DRYING
The granules were dried at 60 till the LOD reached to 4.0 -5.0%
STEP 5 LUBRICATION
• Sift the magnesium stearate was shifted   shifted through  sieve no 40# loaded in 
to the blender.
• The blend was contuniued for 5 mints
• The material was blended for 15 mints
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The blend was unloaded in to HDPE container line with double line poly ethelene bag . the 
container were tightly were closed and weighed .
 CHRATERIZATION OF BLEND
EVALUATION OF FLOW PROPERTIES:-
The flow properties of granules were studied by measuring the angle of repose employing open
tube method,. The angle of repose was calculated by using the following formula
                                              
Tan α=
h
r
 or α= Tan
-1 h
r
                                              Where h = height of the pile, cm   
                                                          r = radius of the base of the pile, cm
BULK DENSITY:-
 Bulk density is the ratio of the  granules to the bulk volume it occupies, expressed in
gm/ml. granules were weighed and poured into a 100ml- measuring cylinder and the volume was
measured.
             Poured bulk density  = Mass of granules
                                                  Volumes packing  
TAPPED DENSITY:-
Tapped  density  determined  by weighed  accurately  5  gm of  the  granules  were  weighed  and
poured  into  a  100ml-measuring  cylinder  and  the  volume  was  measured.  It  was  tapped
mechanically for 100 times till a constant volume bulk volume obtained, which includes the true
volume of granules and void space among the granules
                             Tapped density     =       Mass of granules
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                                                                 Tapped volume of packing
CARR’S INDEX:-
The percentage of compressibility was determined by Carr’s compressibility index.
                     Carr’s index (%) = Tapped density- Bulk density × 100
                                                         Tapped density
HAUSNER’S RATIO:-
Hausner ratio s determined by comparing the tapped density to the bulk density by using
the equation
                                Hausner’s ratio =   Tapped density
                                                            Bulk density
PREPARATION OF METFORMIN HYDROCHLORIDE SR GRANULES 
Working formula41,42   Table No: 6  
S NO NAME OF THE
INGREDIENTS
F1 F2 F3 F4
Dry mix
1 Metformin hydrochloride 500 500 500 500
2 Hypromellose(methocel-
100MCR)
......... 50 40 -
3 Carmellose sodium …….. 20.80 20.80 20.8
0
Binder
4 Hypromellose(Methocel E 
cps)
……. 40 25 25
5 Purified water ………. q.s q.s q.s
Pre-lubrication
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6 Hydroxy prophyl methyl 
cellulose
210 225 210 210
Lubrication
7 Magnesium sterate ……… 10 10 10
STEP 1 SIFTING MATERIALS
          All the ingredients mentioned blow were weighed accordingly to the formula and passed 
through sieve no 40#
S no Ingredients Sieve no
1 Hypromellose (methocel k-100MCR) 40#
2 Carmellose sodium 40#
STEP 2 MILLING
                Metformin hydrochloride was milled through 2.0 mm screen with knife in for ward 
direction
STEP 3 PREPARATION OF BINDER
S no Ingredients
1 Hypromellose (method E 15 cps)
2 Purified water
1,Purified water was taken in the stainless steel container and hypromellose(method E15 cps) 
was dissolved under constant stirring
2,The above solution was mixed with contunious stirring till homogeneous solution was obtained
STEP 4 DRY MIXING
Sifted material was changed in the mixer and milled metformin hydrochloride was added mixed 
in slow speed for 20 minutes.
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STEP 5 GRANULATION
Binder solution was added to the main bowl of the mixer and mixed well until coherent mass 
was obtained.
STEP 6 DRYING
The wet granules were dried at 55 c for 30 minutes . the semi dried granules shifted through the 
16#.the roughage was milled through 2.0  mm screen .
STEP 7 FINAL DRYING
/The shifted granules were dried at 80 c till the LOD was reached to 3.0 -4.0% W/W 
STEP 8 LUBRICATION
1, Sifted hydroxyl propyl methyl cellulose (K -100MCR) were loaded through 40 # in to drum
blender  along shifted material from step 4.
• 2,The granules were blended for 20 mints in a blender.
Magnesium state was filled through 40 # and loaded in to the blender and the blender was 
continued for 5 mints.
The blend was unloaded in to HDPE container line with double line poly ethylene
bag . the container were tightly were closed and weighed and the details were 
recorded.
FORMULATION DEVELOPMENT
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To arive at a formula which will release metformin hydrochloride in the pattern similar data 
given in the table
Time Expected cumulative % of metformin release
        At the end of2hour limit between
At the end of2hour limit between 35-60
At the end of3 hour limit between 45-60
At the end of4 hour limit between 55-80
At the end of5 hour limit between 60-85
At the end of 6 hour limit between 75-90
At the end of 8 hour limit between 80-95
At the end of 10 hour limit not less than 85%
CHARACTERIZATION OF BLEND
The characterization of blend like  Angle of repose, Bulk Density, Tapped Density, Hausener s
ratio and Compressibility Index were performed
 COMPRESSION OF BILAYER TABLET43
STEP 1 cleaning of compression machine
The machine has 2 hopper and all parts of machine inclouding hopper, turret, food shoe,
punches, and die cavity are previously cleaned by iso propyl alcohol and dried
Step 2 fitting of  B-tolling punches
The B-tolling punches are fitted in the holder and the hooper are fitted the position.Adjust
the machine for its weight, hardness and thickness.
Step 3 loading of granules
The two type of granules are loaded hooper separately. The motor driven by 25 rpm. The
metformin hydrochloride part is white in colour and the vildagliptin is      colour
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Step 4 first compression
 The metformin hydrochloride  part  is  compressed first  in  the cavity in  sequence  in  the
granules are lightly granules are lightly compressed and remove the air from the die cavity.
Step 5 second compression
During the second compression the second layer of colour part was deposited on the first
layer.  The  whole  is  compressed  in  to  a  firm  tablet  in  a  normal  way.  During  the
compression  ,weight  variation,  hardness,  thickness,  friability  and  disintegration  test  are
complied.
EVALUATION  OF BILAYER TABLETS
1, WEIGHT VARIATION TEST
                  Weights of  individual 20 tablets  noted and their mean weight is calculated, and the
percentage deviation is calculated by using the formula
           Percent deviation = actual value-average value/ actual value x100
           the limit for weight variation is=±5%
2,THICKNESS
                          Select 10 tablets random and determine the individual thickness of each tablet
with vernier caliper. Calculate the average thickness and record. The average thickness is given
in the table.
Thickness in mm Limits in mm
5.67 5.5±0.3(5.2 to 5.8)
3,DISSOLUTION TEST  
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Dissolution parameters;
Apparatus                      :     USP Apparatus-II (paddle)
Dissolution medium      :      6.8 medium
Volume                          :      900 ml
Speed                             :      75 ml
Temperature                  :      37±0.5 c
Time                              :      30 minutes
Procedure:
            Place 900 ml of 6.8 medium in the vessel and assemble the apparatus. Allow the medium
to equilibrate to a temperature of 37±0.5 c. place one dosage in each vessel, cover the vessel and
operate  the  apparatus  at  the  specified  rate.  After  30  minutes  of  operation  in  6.8  medium,
withdraw an aliquot of the fluid. Perform an analysis of the aliquot using a below described
method.
CHROMATOGRAPHIC SYSTEM:
Column                   : inertsil ODS-3VC18,150mm×4.6,5µ or equivalent
Oven temperature   :1.0ml/min
Detector                 : uv 261 nm
Injection volume    : 20µl
Run time          : 7 mints
Mobile phase :  acetonitrile:buffer(40:60v/v. filter and degas it.
Buffer:     Disodium hydrogen phosphate 28.80 gms and potassium dihydrogen phosphate 11.45 
gms dissolved in water, make up 1000 ml.
Diluents:  dissolution medium
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Standard preparation: 
1, Dissolve about 64 mgm of vildagliptin phosphate in 10 ml dissolution medium, dissolve and 
dilute to 100 ml mobile phase.\
2, Dissolve about 55 mgm of metformin hydrochloride in 10 ml ofdissolution medium,add 10  
ml of solution (1) and make up dissolution medium with 100 ml
Sample preparation:
place one tablet in to each of the six dissolution vessel and start dissolution test.at the specified 
interval ,withdraw about 10 ml of the  sample solution from each dissolution vessel. Filter 
through whatman filter paper no:41 filter and use the solution as sample solution
Procedure:
       Inject 20 µl volumes of blank, standard (6 injections)and sample  (in single) in to the 
chromatograph.record the chromatogram and measure the  peak areas of the sample and the 
standard solution.        
  For Vildagliptin
               Calculate the mg Vildagliptin in tablets from the   following expression
 
                                   AT              WS            10               900               P            407.32     100
                                   AS              100            100              1                 100          523.32      LC      
       
Where,                                        
                             AT = Area of Vildagliptin in sample preparation
                            AS = Area of Vildagliptin in standard preparation
                           WS = weight of Vildagliptin working standard in mg
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                             P =purity of Vildagliptin phosphate on unhydrous basis
407.32 and 523.32 are the molecular weight of Vildagliptin and vildagliptin phosphate.
                             LC  =lable claim
For Metformin hydrochloride
Calculation; calculate the mg metformin hydrochloride in the tablet form the
 following expression =  
                                  AT             WS             900               P                 100
                                  AS             100            100               LC                                                         
                       
        Where,
                       AT = Area of Metformin hydrochloride in sample preparation
                       AT = Area of Metformin hydrochloride in standard preparation
                       WS = weight of Metformin hydrochloride working standard in mg
                           P = purity of Metformin hydrochloride working sample in mg
                .
5,KINETICS STUDY
              Kinetics of  of Metformin hydrochloride  release  from the optimized batch was
analysed by zero order, first order ,higuchi, peppas.
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6. RESULTS AND DISCUSSION
The HPLC chromatogram and the linearity graph for vildagliptin and metformin hydrochloride 
are given in the figure:
Fig no:7
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Vildagliptin linearity curve
% Avg area
50 38172
100 76186
150 114382
FIG ;8 STANDARD CURVE FOR VIDAGLIPTIN
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FIG :9 STANDARD CURVE OF METFORMIN
Ultra College of Pharmacy, Madurai. Page 54
Formulation and Evaluation of Bilayer tablets of Metformin hydrochloride SR and Vildagliptin IR
 
40 60 80 100 120 140 160
0
200000
400000
600000
800000
1000000
1200000
1400000
f(x) = 6981.97x + 140802
R² = 1
 STD CURVE OF METFORMIN
 
Linear ()
conc(%)
A
v
g
 a
re
a
TABLE NO:7  PERCENTAGE OF DRUG RELEASED BY HPLC 
Parts Average area of 
chromatogram
% of drug released Amount of drug 
released
Metformin SR 841010 97.27 486.35
Vildagliptin IR 97925 99.21 49.6
TABLE NO : 8 AVERAGE AREA OF CHROMATOGRAM FOR PERCENTAGE 
PURITY
Formulation Average area of chromatogram for percentage 
purity
STD SAMPLE
Metformin SR 858667 841010
Vildagliptin IR 98815 97925
TABLE NO :9 Evaluation of vildagliptin and metformim in granules are given in the table
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S 
no
Preformulation 
character
vildagliptin Metformin hcl
F1 F2 F3 F4
1 Angle of repose 22.49° 20 ° 22° 21° 21.75°
2 Bulk 
density(g/cc)
0.880 0.843 0.782 0.781 0.751
3 Carr s index(%) 12.54 15.68 15.34 14.59 14.50
4 Hausner ratio 1.12 1.1055 1.1542 1.145
9
1.1251
TABLE NO: 10 Tablets prepared were evaluated for weight and thickness which are given in the
table
 
S NO EVALUATION FORMULATION
F1 F2 F3 F4
1 %Weight
deviation
0.33% 0.60% 0.60% 0.58%
2 Average weight
in (mg)
899 1014 970 940
3 Thickness(mm) 4.9 5.68 5.65 5.64
TABLE NO :11 DISSOLUTION
Time
in
Percentage of drug release  F1,F2,F3,F4
F1 F2 F3 F4
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hour
s
cumulative
amount  of
drug
release
Cumulati
ve  %
release
cumulativ
e amount 
of drug 
release
Cumulative 
% release
cumulativ
e amount 
of drug 
release
Cumulative
% release
cumulati
ve 
amount 
of drug 
release
Cumulativ
e % release
1 340 68 92.21 18.44 95.44 19.08 154.09 30.82
2 406 81 121.4 24.29 135.302 27.06 204.5 40.9
3 450 90 179 35.8 180.22 36.04 246.82 49.36
4 490 98 251.05 50.21 298.85 59.77 331.36 66.27
5 ………….. ………..
………….
………….
.
………….
305.9 61.18 311.25 65.25 368.15 73.63
6 …………. 335.7 67.14 356.6 71.32 399.55 79.9
8 ………… 352.05 70.41 384.2 76.84 418.63 88.5
10 ……….. 381.75 76.35 401.10 80.22 440.45 97.27
FIG NO :10 INVITRO DISSOLUTION DATA FOR F1
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 To get sustained release, HPMC K 100 mcr alone was used and tablet were prepared by direct
compression. the was not sustained beyond 4 hours( table 11,fig:10) . Therefore the formula was
modified with the inclusion of release retardant polymer at  three stages,
Ultra College of Pharmacy, Madurai. Page 57
Formulation and Evaluation of Bilayer tablets of Metformin hydrochloride SR and Vildagliptin IR
1, Intra granular control release polymer HPMC K 100.
2, Extra granular control release polymer HPMC K 100.
3,cross carmellose was included in the intra granular portion.
FIG NO: 11 INVITRO DISSOLUTION FOR F2 
0 2 4 6 8 10 12
0
20
40
60
80
100
120
 INVITRO DISSOLUTION FOR F2
 
TIME (H)
C
U
M
 %
 O
F
 M
E
T
F
O
R
M
IN
 R
E
L
E
A
S
E
Even though F2 release showed prolonged release , the intial release not sufficient and does not
match with the stipulated drug release.(table 11,fig 11) So F3 was prepared with the low level of
intra and extra granular HPMC K100MCR and binding agent % was reduced from 8%-5%.
FIG NO: 12 INVITRO DISSOLUTION FOR F3 
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F3 the release was improved, but did not in the limit(table 11,fig.12) so intra granular HPMC
K100MCR was excluded f4 was prepared.
FIG NO: 13 IN VITRO DISSOLUTION FOR F4 
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The release from F4 was found to be satisfactory.(table 11,fig no13). so release kinetic studies
were perfumed 
FIG NO: 14 INVITRO DISSOLUTION - COMPARISION 
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Kinetics of f4 was done the graphs are given in figures:
TABLE NO:12  DATA FOR KINETIC STUDIES
s.no time Route t Log t %cdr Log %cdr Cum % 
drug 
retained
Log Cum 
% drug 
retained
1 0 0 0 0 0
2 1 1 0 30.82 1.4888 69.1 1.839
3 2 1.414 0.301 40.9 1.611 59.1 1.772
4 3 1.732 0.4771 49.36 1.693 50.6 1.704
5 4 2 0.6020 66.27 1.821 33.73 1.528
6 5 2.236 0.6989 73.63 1.8900 26.37 1.421
7 6 2.449 0.7781 79.9 1.9025 20.1 1.303
8 8 2.828 0.9030 88.5 1.946 11.5 1.190
9 10 3.162 1 97.27 1.9879 2.73 0.8129
FIG NO: 15 LOG CUM % OF METFORMIN RELEASE VS TIME
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FIG NO: 16 ZERO ORDER GRAPH 
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FIG NO: 17 FIRST  ORDER GRAPH 
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FIG NO:18 HIGUCHI PLOT
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FIG :19 PEPPAS PLOT
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Table:13 RESULT OF KINETIC STUDIES FOR OPTIMIZED FORMULATION
S no Formulatio
n
Zero 
order R2
First 
order R2
Higuchi 
R2
 
Koresmaye
r peppas R2
  
Mechanism of drug 
release
1 F3 0.774 0.850 0.990 0.976 Matrix diffusion and 
drug release through 
swollen matrix
        
The release was found to follow matrix diffusion.
7. SUMMARY AND CONCLUSION
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Development  of  oral  controlled  release  dosage  form  for  a  given  drug  involves
optimization of the dosage from characteristics within the inherent constraint of gastro intestinal
(GI) Physiology.
Bi layer tablets have become popular in recent time containing three drugs in a single
dosage from. In the present work Metformin Hydrochloride, Vildagcliption was formulated in
single bi layer tablet for the treatment of diabetic disorders. Among the two Drugs Metformin
Hydrochloride  has  been  used  for  improving  glucose  utilisaton  and  Vildagcliption  for  better
insulin levels.
The present investigation was undertaken to develop once novel daily bilayer tablet of
metformin hydrochloride as a sustained release, vildagliptin as immediate release. 
When the bilayer tablet containing sustained release part and immediate release part is
administered, the immediate release part is used to achieve therapeutic level immediately and it
act as a loading dose. The sustained part releases the drug for prolonged period and acts as the
maintenance dose.
Vildagliptin  was  formulated  with  excipients  for  immediate  release.  Semi  synthetic
cellulose polymers have become very important for controlling the release. Polymer, hydroxyl
propyl  methyl  cellulose  (Methocel  K  -100  MCR)  by  varying  proportions  and  crosslinked
polymers were used to control the release of the drug Metformin HCl. 
A detailed literature survey has been carried out and the clinical effectiveness at the drug
chosen for diabetic disorders as well as the general research work done on control release form.
this has been presented in literature survey chapter (Chapter 2).
In chapter-3 of the thesis the aim, objectives and plan of work are presented. 
In  chapter-4  of  thesis  the  materials  used   and  the  source  and  methods  adopted  for
preparing the controlled release bi layer tablet formulation and their physical characterization as
per  IP specification  are  given.  HPLC was  used  for  analytical  estimation  of   both  the  drug
candidates.
Four different formulations of SR part  of Metformin Hydrochloride and one formulation of IR
part of vildagliptin were prepared and details of the formula used for preparing bi-layer tablet
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were discussed. The tablets were evaluated for their physical parameters like weight variation
test, friability test, thickness test, content uniformity test. percentage drug release determination
was studied. There are five formulations in the present study. There are three formulations in
present study 
All  these  parameters  F1,  F2  ,F3and  F4  the  weight  variation,  friability,  thickness,
disintegration tests was found to be within limits. so the invitro  release of the three drugs from
the bi layer was studied, These results along with physical characterization results are given in
result, and discussion chapter. The dissolution test was carried out for all the 4 batches using in 3
replicates from each batch.
The dissolution of metformin hydrochloride was carried out in pH 6.8 phosphate buffer
for the required time. If any batch released the drug in a pattern different from the specified
limits,    no further  work  was  done  on such  batches  and  all  were   discussed  in  results  and
discussion chapter.
The formulation 4 was only formulation which complies with the stipulated standard
prescribed. As it is the bi layer tablet containing sustained portion with metformin hydrochloride
along with immediate release portion Vildagliptin release also found out by using 900 ml of 6.8
Phosphate buffer medium and Paddle type of apparatus with 50 rpm. The dissolution studies
were carried out for 45 minutes. At the end of 45 minutes, 49.7 mg out of 50mg of Vildagliptin
was found to be released, The results obtained were   found to comply with the official standard
and 99.4% of the drug was released.
The drug release kinetic studies were carried out and the graphs were plotted.
The release of Metformin Hydro Chloride was found to follow matrix diffusion as evidenced by
the linear cumulative % of drug release vs log cumulative % of drug release. The present study
resulted in a successful development of a formulation for once a day dosage form containing
Metformin HCI SR in one layer and Vildagliptin IR in another layer
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